SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Rating of “Buy” from Brokerages

Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) have earned an average recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $68.00.

Several research analysts have commented on SWTX shares. Wedbush increased their price objective on shares of SpringWorks Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Monday, February 26th. JPMorgan Chase & Co. increased their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright increased their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Barclays upped their price target on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Guggenheim began coverage on shares of SpringWorks Therapeutics in a research note on Monday, February 5th. They set a “buy” rating and a $75.00 price objective for the company.

Insider Activity at SpringWorks Therapeutics

In related news, insider Daniel Pichl sold 15,000 shares of SpringWorks Therapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $50.10, for a total value of $751,500.00. Following the completion of the sale, the insider now owns 45,212 shares of the company’s stock, valued at approximately $2,265,121.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.61% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SWTX. TD Asset Management Inc raised its holdings in SpringWorks Therapeutics by 122.1% in the 3rd quarter. TD Asset Management Inc now owns 138,832 shares of the company’s stock worth $3,210,000 after acquiring an additional 76,316 shares during the period. Assetmark Inc. raised its holdings in SpringWorks Therapeutics by 15.6% in the 3rd quarter. Assetmark Inc. now owns 10,814 shares of the company’s stock worth $250,000 after acquiring an additional 1,461 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of SpringWorks Therapeutics by 7.8% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 33,260 shares of the company’s stock worth $769,000 after purchasing an additional 2,400 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of SpringWorks Therapeutics by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,612 shares of the company’s stock worth $37,000 after purchasing an additional 792 shares during the period. Finally, Teacher Retirement System of Texas increased its holdings in shares of SpringWorks Therapeutics by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 9,770 shares of the company’s stock worth $226,000 after purchasing an additional 441 shares during the period.

SpringWorks Therapeutics Trading Down 1.4 %

Shares of SWTX opened at $43.38 on Friday. The firm has a market cap of $3.20 billion, a PE ratio of -8.44 and a beta of 0.83. SpringWorks Therapeutics has a 1-year low of $18.00 and a 1-year high of $53.92. The firm has a fifty day simple moving average of $47.83 and a two-hundred day simple moving average of $37.56.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The firm had revenue of $5.45 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same period last year, the business earned ($1.19) EPS. As a group, research analysts forecast that SpringWorks Therapeutics will post -4.71 EPS for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.